Table 3.
Hemodynamic, metabolic, renal, and cardiac remodeling parameters upon the initial evaluation and at the end of the follow-up after treatment with ARNI.
| Items | Baseline (N = 54) | Follow-up (N = 42) | Mean difference of values ± SD | P |
|---|---|---|---|---|
| SBP (mmHg) | 123.8 | 117.0 | −6.9 ± 11.6 | 0.001 |
| DBP (mmHg) | 73.9 | 69.5 | −4.1 ± 10.9 | 0.04 |
| HR (bpm) | 65.1 | 62.0 | −2.57 ± 7.21 | 0.04 |
| Glycemia (mg/dL) | 115.3 | 101.5 | −15.9 ± 21.3 | 0.001 |
| HbA1c (%) | 5.9 | 5.4 | −0.36 ± 0.31 | 0.04 |
| eGFR (ml/min/1.73 m2) | 64.8 | 70.1 | 8.46 ± 7.9 | 0.04 |
| NT-pro BNP (pg/mL) | 5503.8 | 3107.1 | −2740.2 ± 1760.1 | 0.001 |
| Uricemia (mg/dL) | 6.21 | 5.92 | −0.31 ± 0.23 | 0.04 |
| EF (%) | 29.8 | 42.1 | 11.7 ± 6.1 | 0.001 |
| End-systolic volume (mL) | 123.12 | 83.1 | −39.8 ± 25.1 | 0.014 |
| End-diastolic volume (mL) | 173.3 | 144.2 | −29.3 ± 19.7 | 0.002 |
| LVMI (g/m2) | 152.4 | 147.8 | −4.68 ± 2.19 | 0.001 |
ARNI, angiotensin receptor-neprilysin inhibitor; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HR, heart rate; eGFR, glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation; EF, ejection fraction; LVMI, left ventricular mass index.